Stocks Health care INBS
NASDAQ · Health careIntelligent Bio Solutions Inc. (INBS)
Intelligent Bio Solutions Inc. reported revenue of $4.2M in fiscal 2026, up 38.1% from a year earlier. It posted a net loss of $12.4M. In fiscal 2026 capital spending exceeded operating cash flow by $12.1M. At June 30, 2026 it held $4M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on August 19, 2026.
Key facts about Intelligent Bio Solutions Inc.
- Net worth
- Intelligent Bio Solutions Inc. has a market value (market cap) of $5M at the latest share price, and shareholders' equity of $5.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $4.2M (+38.1% year on year), with a net loss of $12.4M.
- Cash flow
- In fiscal 2026 operations used $11.9M of cash.
- Latest report
- The latest periodic report (annual report, 10-K) was filed with the SEC on August 19, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Intelligent Bio Solutions Inc.'s next report is expected around November 24, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Intelligent Bio Solutions Inc. does
Intelligent Bio Solutions Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker INBS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $4.2M | -$12.4M | -$8.44 | -$12.1M |
| 2025 | $3.1M | -$10.6M | -$20.04 | -$9.9M |
| 2024 | $3.1M | -$10.2M | -$63.93 | -$9.8M |
| 2023 | $1.3M | -$10.6M | -$1,272.54 | n/a |
| 2022 | $437.1K | -$8.3M | -$1,362.75 | n/a |
| 2021 | $2M | -$7M | -$81.79 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where INBS ranks in Health care
Latest SEC filings
What Intelligent Bio Solutions Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026
- September 11, 2026Other event 8-K
- September 9, 2026
- September 2, 2026
- September 1, 2026
- August 28, 2026
- August 19, 2026
- August 19, 2026Annual report 10-K · period to June 30, 2026Revenue rose 38% to $4.2M versus the prior year; diluted EPS -$8.44 versus -$20.04.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
Insider trades
What the people running Intelligent Bio Solutions Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 18, 2026 | Simeonidis HarryChief Executive Officer | Received as pay | 9,150 | - |
| March 18, 2026 | Simeonidis HarryChief Executive Officer | Received as pay | 21,350 | - |
| March 18, 2026 | Hurd Jonathan ScottDirector | Received as pay | 5,000 | - |
| March 18, 2026 | Isenberg JasonDirector | Received as pay | 5,000 | - |
| March 18, 2026 | Sakiris Spiro KevinChief Financial Officer | Received as pay | 9,150 | - |
| March 18, 2026 | Sakiris Spiro KevinChief Financial Officer | Received as pay | 21,350 | - |
| March 18, 2026 | Fraser Nicola MarionDirector | Received as pay | 5,000 | - |
| March 18, 2026 | Boyages Steven ConstantineDirector | Received as pay | 5,000 | - |
Who owns INBS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Alyeska Investment Group, L.P.13G, passive with 2 related filers | 9.99% | November 14, 2025 |
| Armistice Capital, LLC13G, passive with 1 related filers | 5.91% | August 14, 2026 |
Largest institutional holders
Insiders
6 insiders reported holding 88,558 shares in total, about $186K at the last price.
| Holder | Shares |
|---|---|
| Simeonidis HarryChief Executive Officer | 34,540 |
| Sakiris Spiro KevinChief Financial Officer | 33,981 |
| Boyages Steven ConstantineDirector | 5,031 |
| Hurd Jonathan ScottDirector | 5,006 |
| Isenberg JasonDirector | 5,000 |
| Fraser Nicola MarionDirector | 5,000 |
Questions about INBS
What does Intelligent Bio Solutions Inc. do?
Intelligent Bio Solutions Inc. is a company in the Health care sector, listed on NASDAQ as INBS. Its shares trade on NASDAQ under the ticker INBS.
What is Intelligent Bio Solutions Inc.'s net worth?
Intelligent Bio Solutions Inc. has a market value (market cap) of $5M at the latest share price, and shareholders' equity of $5.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Intelligent Bio Solutions Inc. profitable?
No. In fiscal 2026 it reported a net loss of $12.4M on revenue of $4.2M.
How much revenue does Intelligent Bio Solutions Inc. make?
In fiscal 2026 Intelligent Bio Solutions Inc. reported revenue of $4.2M. That is 38.1% more than a year earlier.
When did Intelligent Bio Solutions Inc. last report?
Its most recent periodic report is the annual report (10-K) filed on August 19, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shelf registration to sell securities from September 15, 2026.
When is Intelligent Bio Solutions Inc.'s next earnings report?
Intelligent Bio Solutions Inc.'s next report is expected around November 24, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare INBS with
Follow INBS
Get an email when Intelligent Bio Solutions Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Intelligent Bio Solutions Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.